VEGFA and neoplasm: Patients harboring tumor genomic markers predicting poor outcomes to VEGF targeted therapy may be candidates for agents targeting primarily non-VEGF pathways, such as checkpoint inhibitors, c-MET inhibitors, a combination of VEGF-TKI plus checkpoint inhibitors, or clinical trials.